PATENT CLAIM ANALYSIS

Application Number: 16203507
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-10
Patent Classification: ["514", "020800"]

Abstract:
The disclosure generally describes methods of preventing or treating dominant optic atrophy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. The present technology relates generally to the treatment or prevention of Leber's hereditary optic neuropathy (LHON) or dominant optic atrophy (DOA) in mammals through administration of therapeutically effective amounts of aromatic-cationic peptides to subjects in need thereof. In one aspect, the present disclosure provides a method of treating or preventing dominant optic atrophy in a mammalian subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide.

Claim (Index 3):
The method of  claim 1 , wherein the peptide is administered intraocularly, iontophoretically, orally, topically, systemically, intravenously, subcutaneously, or intramuscularly.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 98.0
- Lexical Diversity: 2.05455
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15401527', '14671538', '13897070', '13634192', '12367267']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7839812495079813
- 35 USC 102 Novelty (BERT): 0.5022676585387459
- Combined Prediction Score: 0.7558098904110577
- Mean Citation Score: 274.379584
- Max Citation Score: 284.26874
- Similarity Product: 243.40336003131387

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test